A new 1mg strength formulation of ‘Abilify’ can now be prescribed at general hospitals

According to industry sources, Korea Otsuka Pharmaceutical's antipsychotic ‘Abilify (aripiprazole)’ has passed the drug committees (DCs) of major hospitals in Korea, including the Seoul National University Hospital, Seoul Asan Medical Center, and Sinchon Severance Hospital.

The company has been working to make prompt entry into the market after receiving reimbursement approval for its new strength in March this year.

The 2mg, 5mg, 10mg, and 15mg strengths of Abilify have already been approved in the past. The introduction of the 1mg strength is the first change made in the product li